Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Remke

Showing results (141-150 of 184) with videos related to

Pageof 19
Sort By:
ACS Central Science|June 3, 2021
Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma ProgressionJoão Conde, Ruth A Pumroy, Charlotte Baker, et al.
Nature Communications|November 24, 2023
Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signaturesMelanie Schoof, Shweta Godbole, Thomas K Albert, et al.
Nature Communications|December 6, 2022
Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastomaMichelle M Kameda-Smith, Helen Zhu, En-Ching Luo, et al.
Cancer Cell|December 3, 2015
MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing ChromatinMarco Gallo, Fiona J Coutinho, Robert J Vanner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade gliomaMatthew Mistry, Nataliya Zhukova, Daniele Merico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2022
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in GlioblastomaSied Kebir, Vivien Ullrich, Pia Berger, et al.
Science Translational Medicine|March 17, 2017
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumorsSharareh Gholamin, Siddhartha S Mitra, Abdullah H Feroze, et al.
Cancer Cell|September 3, 2019
Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and RelapseLiguo Zhang, Xuelian He, Xuezhao Liu, et al.
Cell Death & Disease|September 29, 2021
The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastomaUlvi Ahmadov, Daniel Picard, Jasmin Bartl, et al.
Journal for Immunotherapy of Cancer|January 13, 2023
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammationViktoria Marquardt, Johanna Theruvath, David Pauck, et al.
Pageof 19

Showing results (141-150 of 184) with videos related to

Sort By:
Pageof 19
ACS Central Science|June 3, 2021
Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma ProgressionJoão Conde, Ruth A Pumroy, Charlotte Baker, et al.
Nature Communications|November 24, 2023
Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signaturesMelanie Schoof, Shweta Godbole, Thomas K Albert, et al.
Nature Communications|December 6, 2022
Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastomaMichelle M Kameda-Smith, Helen Zhu, En-Ching Luo, et al.
Cancer Cell|December 3, 2015
MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing ChromatinMarco Gallo, Fiona J Coutinho, Robert J Vanner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade gliomaMatthew Mistry, Nataliya Zhukova, Daniele Merico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2022
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in GlioblastomaSied Kebir, Vivien Ullrich, Pia Berger, et al.
Science Translational Medicine|March 17, 2017
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumorsSharareh Gholamin, Siddhartha S Mitra, Abdullah H Feroze, et al.
Cancer Cell|September 3, 2019
Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and RelapseLiguo Zhang, Xuelian He, Xuezhao Liu, et al.
Cell Death & Disease|September 29, 2021
The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastomaUlvi Ahmadov, Daniel Picard, Jasmin Bartl, et al.
Journal for Immunotherapy of Cancer|January 13, 2023
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammationViktoria Marquardt, Johanna Theruvath, David Pauck, et al.
Pageof 19